Therapeutic Vision, Inc. is a small company that is focused on the development of pharmaceuticals primarily for the companion animal market and eventually their owners. We are developing age-related and diabetic therapies for the preservation of vision and the prevention of neurodegeneration.
Our staff has experts who are prepared to help you solve your toxicological problems linked to cataract development. Through our CRO services, we can also help you to obtain FDA approval for your veterinary drug candidate by helping you to tackle the FDA regulatory requirements.
Therapeutic Vision, Inc. (TVI)
Therapeutic Vision strives to provide you with cutting edge medications to maintain your pets vision.
Our research team with vision research and veterinary ophthalmology expertise are developing drugs to preserve the vision of your aging and diabetic patients that are backed with strong experimental evidence.
- 9/1/2015 TVI has received an SBIR Phase 2B grant from the National Eye Institute to develop Kinostat®.
- 9/17/15 TVI received a Business innovation Award from the NE Dept. of Economic Development to develop Kinostat.
- 11/2015 TVI inventors received approval from the US Patent Office for the use of Kinostat in both animals and humans.
- 3/3/16 TVI has been chosen by the SBIR Office of the National Institutes of Health to be showcased in the Innovation Zone for the 2016 BIO International Convention to be held in San Francisco, June 6-9, 2016.